

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>JOHNSON & JOHNSON</u> <hr/> (Last) (First) (Middle) ONE JOHNSON & JOHNSON PLAZA <hr/> (Street) NEW BRUNSWICK NJ 08933 <hr/> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 06/25/2020	3. Issuer Name and Ticker or Trading Symbol <u>Fusion Pharmaceuticals Inc. [FUSN]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Class A Preferred Shares	(1)	(1)	Common Shares	1,997,876	(1)	I	By Johnson & Johnson Innovation - JJDC, Inc. ⁽²⁾
Class B Preferred Shares	(3)	(3)	Common Shares	947,640	(3)	I	By Johnson & Johnson Innovation - JJDC, Inc. ⁽²⁾
Warrants to purchase Class B Preferred Shares	01/10/2020 ⁽⁴⁾	01/10/2022 ⁽⁴⁾	Common Shares	89,118	8.1 ⁽⁴⁾	I	By Johnson & Johnson Innovation - JJDC, Inc. ⁽²⁾

1. Name and Address of Reporting Person* <u>JOHNSON & JOHNSON</u> <hr/> (Last) (First) (Middle) ONE JOHNSON & JOHNSON PLAZA <hr/> (Street) NEW BRUNSWICK NJ 08933 <hr/> (City) (State) (Zip)		
--	--	--

1. Name and Address of Reporting Person* <u>Johnson & Johnson Innovation - JJDC,</u>

Inc.

(Last) (First) (Middle)

410 GEORGE STREET

(Street)

NEW BRUNSWICK NJ 08901

(City) (State) (Zip)

Explanation of Responses:

1. The Class A Preferred Shares are convertible into Common Shares on a one-for-5.339 basis. Upon the closing of the Issuer's initial public offering, the Class A Preferred Shares will convert into the number of Common Shares reported in Column 3, for no additional consideration. The Class A Preferred Shares have no expiration date.
2. The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person.
3. The Class B Preferred Shares are convertible into Common Shares on a one-for-5.339 basis. Upon the closing of the Issuer's initial public offering, the Class B Preferred Shares will convert into the number of Common Shares reported in Column 3, for no additional consideration. The Class B Preferred Shares have no expiration date.
4. Upon the closing of the Issuer's initial public offering, the Warrants to purchase Class B Preferred Shares will become Warrants to purchase Common Shares at an exercise price of \$8.10 per share.

Remarks:

Johnson & Johnson By: /s/
Matthew Orlando, 06/25/2020
Secretary

Johnson & Johnson
Innovation - JJDC, Inc. 06/25/2020
By: /s/ Kevin Norman,
Assistant Secretary

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.